Inhibitors of fatty acid uptake and methods of use
The present disclosure describes inhibitors of fatty acid uptake and methods of using such inhibitors. Specifically, the present disclosure describes inhibitors with specificity for FATP2.
1. A method of inhibiting fatty acid uptake by cells, comprising:
contacting said cells with a compound having the formula:
or a pharmaceutically acceptable salt form thereof, wherein:
R 1 is H or NO 2 ; and
R 2 is selected from the group consisting of: H, Cl, and OCH 3 .
2. The method of claim 1 , wherein said cells are selected from the group consisting of intestinal epithelial cells and hepatocytes.
3. The method of claim 1 , wherein said contacting is in vitro.
4. The method of claim 1 , wherein said inhibition is reversible.
5. The method of claim 1 , wherein R 1 is NO 2 .
6. The method of claim 1 , wherein R 2 is Cl.
7. The method of claim 1 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt form thereof.
8. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt form thereof.
9. A method of treating a disease selected from the group consisting of obesity, metabolic syndrome, insulin resistant diabetes, cardiovascular disease, and non-alcoholic fatty liver disease in an individual, comprising:
administering, to said individual, a compound having the formula:
or a pharmaceutically acceptable salt form thereof, wherein:
R 1 is H or NO 2 ; and
R 2 is selected from the group consisting of: H, CI, and OCH 3 .
10. The method of claim 9 , wherein R 1 is NO 2 .
11. The method of claim 9 , wherein R 2 is Cl.
12. The method of claim 9 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt form thereof.
13. The method of claim 9 , wherein the compound is:
or a pharmaceutically acceptable salt form thereof.
14. A method of inhibiting FATP2 in a cell, the method comprising:
contacting said cell with a compound having the formula:
or a pharmaceutically acceptable salt form thereof, wherein:
R 1 is H or NO 2 ; and
R 2 is selected from the group consisting of: H, Cl, and OCH 3 .
15. The method of claim 14 , wherein said cell is selected from the group consisting of intestinal epithelial cells and hepatocytes.
16. The method of claim 14 , wherein said contacting is in vitro.
17. The method of claim 14 , wherein said inhibition is reversible.
18. The method of claim 14 , wherein R 1 is NO 2 .
19. The method of claim 14 , wherein R 2 is Cl.
20. The method of claim 14 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt form thereof.
21. The method of claim 14 , wherein the compound is:
or a pharmaceutically acceptable salt form thereof.